Lataa...
Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part I
With the central importance of antiplatelet therapy in patients with coronary artery disease and the numerous positive trials with glycoprotein (GP) IIb/IIIa inhibitors given intravenously, it was hoped that one could extend the benefit of IIb/IIIa inhibition to long‐term treatment. Although the hyp...
Tallennettuna:
| Julkaisussa: | Clin Cardiol |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Wiley Periodicals, Inc.
2006
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654758/ https://ncbi.nlm.nih.gov/pubmed/12918637 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4950260803 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|